BUFFALO GROVE, Ill., July 14, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced positive data from a 3-D Cancer Cell Proliferation Assay with RES-529 and three analogs. The assay confirmed RES-529 activity for the lead indication of glioblastoma, while also demonstrating activity in several other oncology cell lines.
3-D cultures grown under physiologically relevant conditions enhance the predictive value for in vivo activity. RestorGenex's lead compound, RES-529, is a proprietary first-in-class PI3K/Akt/mTOR pathway inhibitor that interferes with the molecular components that form TORC1 and TORC2. RES-529 prevents these complexes from generating and potentiating signaling, a characteristic associated with tumor growth and metastasis. In addition, the three RES-529 analogs tested showed activity in a variety of cell lines.
"We were pleased to see consistent inhibition of tumor cell growth by RES-529 for all four of the brain cancer cell lines tested. In addition, we saw activity in several other tumor types including breast, lung, and prostate in which prior publications have described both in vitro and in vivo efficacy for RES-529," stated Mark Weinberg, MD, MBA, senior vice president of clinical development for RestorGenex. RES-529 received orphan drug designation for the treatment of glioblastoma multiforme in early 2015 and is expected to enter Phase I clinical trials in 2016.
Stephen M. Simes, chief executive officer of RestorGenex added, "The scientific research and knowledge of RES-529 continues to expand, in particular for clinical oncology applications. Our intended plan is to conduct a Phase 1b/2a study of RES-529 in glioblastoma followed by Phase 2a studies in other tumor types, including breast, lung and prostate cancers. These new data help to validate our plans for future studies with RES-529, as well as suggest that its analogs could also be developed for oncology indications."
About RestorGenex Corporation
RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the oncologic, ophthalmologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information please see: www.restorgenex.com.
Forward Looking Statements
Certain statements in this release are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the potential benefits of RES-529 and RestorGenex's anticipated clinical work in 2016 and other statements that are not historical in nature, particularly those that utilize terminology such as "expects," intends," "plans," "anticipates," "will," "may," "could," "future," "continue," "show promise," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Risks and uncertainties may cause RestorGenex's actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular risks and uncertainties include, among others, uncertainties involved in clinical testing, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, RestorGenex's ability to license out its existing products and technologies and license in additional products and technologies and the terms of such licenses; and other risks and uncertainties described in RestorGenex's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K for the fiscal year ended December 31, 2014 and subsequent quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2015. All forward-looking statements in this release speak only as of the date of this release and are based on RestorGenex's current beliefs and expectations. RestorGenex undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.